Physician profile
Peter Brooks Schock
NPI 1821160946
$3,391.33
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $944 · 2021: $210 · 2022: $102 · 2023: $577 · 2024: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $281.55 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $258.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $222.35 | 2019-2020 | |
| Novo Nordisk INC | $217.17 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $210.08 | 2021-2024 | Qulipta, Ubrelvy, Liletta |
| Lilly USA, LLC | $198.82 | 2019-2024 | Jardiance, Mounjaro |
| Amgen INC. | $179.78 | 2019-2022 | |
| Astellas Pharma US INC | $152.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $140.41 | 2019-2023 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $135.43 | 2019-2023 | Seglentis, Livalo |
| Antares Pharma, INC. | $133.71 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Allergan, INC. | $101.68 | 2019-2020 | |
| Esperion Therapeutics, INC. | $96.64 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.21 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $79.83 | 2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Schock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.